Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians

Table 1 Descriptive data of the studied hepatocellular carcinoma patients

			HCC
			N = 70
Demographic data	Age (yr)		62.0 ± 7.6
	Gender (%)	Female	22 (31.4)
		Male	48 (68.6)
	Smoker (%)	No	56 (80.0)
		Yes	14 (20.0)
	DM	No	52 (74.3)
	(%)	Yes	18 (25.7)
	BMI (kg/m2)		27.7 (23.6- 31.9)
Laboratory investigation	Hb (g/dL)		13.2 ± 1.9
	WBC (× 103/µL)		6.0 (4.6-8.0)
	Platelets (× 103/µL)		169.5 ± 77.9
	ALT (U/mL)		52.5 (32.0- 74.3)
	AST (U/mL)		60.5 (38.0- 83.3)
	Alb (g/dL)		3.7 ± 0.5
	Bil.T (mg/dL)		0.9 (0.6- 1.4)
	AFP (ng/dL)		38.8 (10.0- 370.0)
	Creatinine (mg/dL)		0.9 ± 0.2
BCLC (%)	Early		34 (48.6)
	Intermediate		23 (32.9)
	Late		13 (18.6)
Performance status (%)	0		43 (61.4)
	1		24 (34.3)
	2		2 (2.9)
	3		1 (1.4)
Child grade (%)	A		58 (82.9)
	B		11 (15.7)
	C		1 (1.4)
Child score			5.8 ± 1.0
Number of HCCs (%)	Single		49 (70.0)
	Two		12 (17.1)
	≥ 3		9 (12.9)
Site of HCC (%)	Right lobe		59 (84.3)
	Left lobe		7 (10.0)
	Both lobes		4 (5.7)
HCC size (cm)			4.0 (2.7- 5.0)
Portal vein	Patent		65 (92.9)
(%)
	Thrombosed		5 (7.1)
Abdominal lymphadenopathy	No		65 (92.9)
(%)	Yes		5 (7.1)
Decision of treatment	Best supportive care		7 (10.0)
	Combined therapy		1 (1.4)
(%)	Hepatectomy		3 (4.3)
	Microwave ablation		20 (28.5)
	Radioembolization		3 (4.3)
	Sorafinib		3 (4.3)
	TACE		29 (41.4)
Response to treatment according to mRECIST (%)	Stationary		4 (7.8)
	Partial response		7 (13.7)
	Complete response		34 (66.7)
	Progressive disease		6 (11.8)
Clinical decompensation (%)	Yes		9 (12.9)
	No		61 (54.5)
Alive or dead (%)	Dead		34 (48.6)
	Alive		36 (51.4)
Survival (days)			367.1 ± 173.9
miRNA-326			35.0 (12.5- 162.3)
miRNA-511			1.2 (0.3- 3.2)
miRNA-424			5.1 (2.9- 10.3)

DM: Diabetes mellitus; Hb: Hemoglobin; WBCs: White blood cells; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; INR: International nationalized ratio; AFP: α-fetoprotein; HCC: Hepatocellular carcinoma; BCLC: Barcelona clinic liver cancer; MWA: Microwave ablation; TACE: Trans-arterial chemoembolization; mRECIST: Modified response evaluation criteria in solid tumors; miRNA: MicroRNA.